Text Size

SHARE: Simple HAART With Abacavir, Reyataz, and Epivir

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2007 by Clinical Alliance for Research & Education - Infectious Diseases, LLC..
Recruitment status was  Recruiting
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by:
Clinical Alliance for Research & Education - Infectious Diseases, LLC.
ClinicalTrials.gov Identifier:
NCT00426296
First received: January 23, 2007
Last updated: October 30, 2007
Last verified: October 2007
History of Changes
  Purpose

SHARE: Simple HAART with Abacavir, Reyataz, and Epivir


Condition Intervention Phase
HIV Infections
Lipodystrophy
 Drug: atazanavir (Reyataz)
Drug: ritonavir (Norvir)
 Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Further study details as provided by Clinical Alliance for Research & Education - Infectious Diseases, LLC.:

Study Start Date: August 2006
Detailed Description:

Open-label, multicenter study of ABC/3TC + ATV in subjects who have completed at least 24 weeks of treatment on ABC/3TC+ATV/RTV as their first line regimen and have plasma HIV-1 RNA <50 copies/mL at entry

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir (Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen
  • Viral load <50 copies/ml

Exclusion Criteria:

  • Viral load >50 copies/ml
  • Having taken more than one antiretroviral regimen
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00426296

Contacts
Contact: Richard A. Elion, MD drrelion@aol.com

Locations
United States, District of Columbia
Whitman-Walker Clinic Recruiting
Washington, District of Columbia, United States
Contact: Richard Elion, MD         drrelion@aol.com    
Principal Investigator: Richard A Elion, MD            
Sponsors and Collaborators
Clinical Alliance for Research & Education - Infectious Diseases, LLC.
GlaxoSmithKline
Investigators
Principal Investigator: Richard A Elion, MD Whitman-Walker Clinic
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00426296     History of Changes
Other Study ID Numbers: COL102060
Study First Received: January 23, 2007
Last Updated: October 30, 2007
Health Authority: United States: Institutional Review Board

Keywords provided by Clinical Alliance for Research & Education - Infectious Diseases, LLC.:
HIV
Reyataz
atazanavir
Norvir
 ritonavir
Boosted
Lipodystrophy
Treatment Experienced

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lipodystrophy
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Skin Diseases, Metabolic
Skin Diseases
Lipid Metabolism Disorders
 Metabolic Diseases
Ritonavir
Atazanavir
Abacavir
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Reverse Transcriptase Inhibitors

ClinicalTrials.gov processed this record on March 07, 2013